首页 | 本学科首页   官方微博 | 高级检索  
检索        

PI3K/mTOR双重抑制剂的研究进展
引用本文:宣 伟,邵 藤,李义平,张三奇.PI3K/mTOR双重抑制剂的研究进展[J].现代药物与临床,2012,27(2):133-137.
作者姓名:宣 伟  邵 藤  李义平  张三奇
作者单位:西安交通大学医学院药学系
摘    要:磷脂酰肌醇3-激酶/哺乳动物雷帕霉素靶蛋白(phosphoinosmde-3-kinase/the mammalian target of rapamycin,PI3K/mTOR)双重抑制剂已经成为抗肿瘤药物研发的热点之一。本文介绍芳基脲类和3-吡啶基杂环类等PI3K/mTOR双重抑制剂的化学结构,根据其结构特点及其与PI3Kγ共结晶模式,剖析了两类抑制剂药效团的基本结构。

关 键 词:PI3K/mTOR双重抑制剂  药效团  抗肿瘤药物

Research progress on PI3K/mTOR dual inhibitors
XUAN Wei,SHAO Teng,LI Yi-ping and ZHANG San-qi.Research progress on PI3K/mTOR dual inhibitors[J].Drugs & Clinic,2012,27(2):133-137.
Authors:XUAN Wei  SHAO Teng  LI Yi-ping and ZHANG San-qi
Institution:Department of Pharmacy,School of Medicine,Xi’an Jiaotong University,Xi’an 710061,China
Abstract:phosphoinosmde-3-kinase/the mammalian target of rapamycin(PI3K/mTOR) dual inhibitor is emerging as a hotspot in antitumor drugs research.This review introducesthe chemical structures of PI3K/mTOR dual inhibitors which can be sorted into arylureas and 3-pyridinyl heterocycles.The basic pharmacophore structures were suggested according to the structure characteristics of dual inhibitor and tits co-crystal structure with PI3K.
Keywords:phosphoinosmde-3-kinase/the mammalian target of rapamycin(PI3K/mTOR) dual inhibitor  pharmacophore  antitumor drugs
本文献已被 CNKI 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号